Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Epidemiology of TB in 21st century
3. Estimated TB incidence rates, 2010
4. Countries with XDR-TB confirmed cases
5. Global plan to stop TB: 2006 - 2015
6. Bacille Calmette-Guerin
7. Efficacy of BCG
8. BCG protective efficacy – meta analysis
9. Why doesn’t BCG work?
10. Environmental mycobacteria: evidence for masking
11. Blocking
12. Other problems with BCG
13. Tuberculosis in humans
14. What do we know about protective immunity
15. Design of an improved vaccine against TB
16. Recombinant BCG strains
17. Attenuated M.tb strains
18. Booster vaccines: MTB 72F/M72
19. Booster vaccines: SSI fusion proteins
20. Booster vaccines: Aeras 402
21. MVA85A
22. Improving BCG induced protection by MVA85A
23. Ag85A-specific cultured ELISPOT responses data
24. In vitro Ag85A-induced IFN-g and IL-17 levels
25. Stages of clinical development
26. Robert Koch
27. Design of studies with MVA85A
28. Target populations
29. Summary of MVA85A clinical trials since 2002
30. Safety data
31. BCG – MVA85A induced immune response
32. CD4+ T cell epitopes recognised after vaccination
33. Priming with BCG and boosting with MVA data
34. MVA induced T cells are highly polyfunctional
35. IL-17 and TB
36. Antigen-85A specific IL-17 responses
37. MVA85A in M.tb latently infected adults
38. MVA85A in latently infected and in vaccinated
39. Trials in South Africa
40. MVA85A is immunogenic in South African trials
41. Co-administration of MVA85A with EPI vaccines
42. Infant Phase IIb efficacy trial
43. Trials in HIV-infected adults
44. HIV safety data
45. MVA85A induces a polyfunctional profile
46. Phase IIb trial in HIV-positive adults
47. Progress
48. Challenges
49. Acknowledgements
50. Funders and partners

Topics Covered

• Review of the current vaccine, BCG
• Potential reasons for variability
• Leading approaches to developing a new TB vaccine
• Clinical development of MVA85A

Links

Series:

• Respiratory Infection

Categories:

• Immunology
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases
• Respiratory Diseases
• Vaccines

Talk Citation

Publication History

• Published on July 11, 2013

Financial Disclosures

• Prof. Helen McShane has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.